Cerevel Therapeutics - CERE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $41.40
  • Forecasted Upside: -1.08%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$41.85
▼ -0.16 (-0.38%)

This chart shows the closing price for CERE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cerevel Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CERE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CERE

Analyst Price Target is $41.40
▼ -1.08% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Cerevel Therapeutics in the last 3 months. The average price target is $41.40, with a high forecast of $45.00 and a low forecast of $30.00. The average price target represents a -1.08% upside from the last price of $41.85.

This chart shows the closing price for CERE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 10 investment analysts is to hold stock in Cerevel Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
10/20/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
1/18/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
4/18/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
7/17/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
10/15/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
1/13/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
4/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2024MizuhoBoost TargetNeutral ➝ Neutral$25.00 ➝ $45.00Low
12/28/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$25.00 ➝ $45.00Low
12/22/2023Jefferies Financial GroupReiterated RatingBuy ➝ Hold$40.00 ➝ $45.00Low
12/8/2023TD CowenReiterated RatingOutperform ➝ Market Perform$45.00Low
12/7/2023HC WainwrightDowngradeBuy ➝ Neutral$41.00 ➝ $45.00Low
12/7/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral$38.00 ➝ $45.00Low
12/7/2023Piper SandlerReiterated RatingOverweight ➝ Neutral$33.00 ➝ $45.00Low
11/20/2023JPMorgan Chase & Co.Reiterated RatingNeutral$25.00Low
11/2/2023Morgan StanleyLower TargetOverweight ➝ Overweight$42.00 ➝ $38.00N/A
9/27/2023Piper SandlerInitiated CoverageOverweight$33.00Low
8/7/2023MizuhoLower TargetNeutral ➝ Neutral$29.00 ➝ $25.00Low
8/3/2023Morgan StanleyLower TargetOverweight ➝ Overweight$46.00 ➝ $42.00Low
8/3/2023Bank of AmericaDowngradeBuy ➝ Neutral$36.00 ➝ $31.00Low
8/3/2023HC WainwrightLower TargetBuy ➝ Buy$45.00 ➝ $41.00Low
5/8/2023MizuhoBoost Target$26.00 ➝ $29.00Low
5/4/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$30.00Low
4/10/2023TD CowenInitiated CoverageOutperformLow
4/3/2023HC WainwrightReiterated RatingBuy$45.00Low
3/17/2023JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$40.00 ➝ $29.00Low
3/16/2023Berenberg BankInitiated CoverageHold$22.00Low
3/9/2023MizuhoLower TargetNeutral$28.00 ➝ $26.00Low
2/23/2023Morgan StanleyLower TargetOverweight$50.00 ➝ $40.00Low
2/23/2023HC WainwrightLower TargetBuy$48.00 ➝ $45.00Low
2/22/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$38.00 ➝ $30.00Low
12/20/2022Cantor FitzgeraldBoost Target$41.00 ➝ $46.00Low
12/6/2022JPMorgan Chase & Co.Lower TargetOverweight$49.00 ➝ $40.00Low
11/10/2022MizuhoLower TargetNeutral$32.00 ➝ $28.00Low
11/9/2022HC WainwrightLower TargetBuy$50.00 ➝ $48.00N/A
11/1/2022Loop CapitalInitiated CoverageBuy$40.00Low
10/20/2022Bank of AmericaInitiated CoverageBuy$39.00Low
9/29/2022Cantor FitzgeraldInitiated CoverageOverweight$41.00Low
9/26/2022Wells Fargo & CompanyInitiated CoverageOverweight$38.00Low
9/21/2022The Goldman Sachs GroupBoost TargetNeutral$24.00 ➝ $28.00Low
9/12/2022Evercore ISIInitiated CoverageOutperformLow
8/23/2022MizuhoBoost TargetNeutral$27.00 ➝ $32.00Low
8/22/2022Morgan StanleyBoost TargetOverweight$39.00 ➝ $50.00Low
8/3/2022MizuhoLower TargetNeutral$30.00 ➝ $27.00N/A
7/6/2022MizuhoInitiated CoverageNeutral$30.00N/A
5/24/2022The Goldman Sachs GroupLower TargetNeutral$28.00 ➝ $20.00Medium
2/15/2022The Goldman Sachs GroupInitiated CoverageNeutral$27.00High
1/5/2022JPMorgan Chase & Co.Initiated CoverageOverweight$50.00Medium
12/16/2021HC WainwrightInitiated CoverageBuy$50.00High
11/10/2021Stifel NicolausBoost TargetBuy$33.00 ➝ $50.00High
10/8/2021Jefferies Financial GroupBoost TargetBuy$30.00 ➝ $37.00Low
9/7/2021Morgan StanleyBoost TargetOverweight$27.00 ➝ $39.00High
7/13/2021Stifel NicolausBoost TargetPositive ➝ Buy$21.00 ➝ $33.00Medium
6/18/2021Morgan StanleyInitiated CoverageOverweight$27.00High
12/10/2020The Goldman Sachs GroupInitiated CoverageBuy$24.00N/A
11/24/2020SidotiDowngradeHoldN/A
11/23/2020Jefferies Financial GroupInitiated CoverageBuy$18.00N/A
11/9/2020Stifel NicolausInitiated CoverageBuy$17.00N/A
(Data available from 4/12/2019 forward)

News Sentiment Rating

1.06 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/15/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/15/2023
  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/14/2023
  • 8 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/14/2023
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/13/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/12/2024
  • 8 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/13/2024
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/12/2024

Current Sentiment

  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Cerevel Therapeutics logo
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $41.85
Low: $41.50
High: $42.05

50 Day Range

MA: $41.96
Low: $40.88
High: $43.27

52 Week Range

Now: $41.85
Low: $19.59
High: $43.59

Volume

2,114,740 shs

Average Volume

1,538,757 shs

Market Capitalization

$7.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Cerevel Therapeutics?

The following sell-side analysts have issued stock ratings on Cerevel Therapeutics in the last year: Bank of America Co., Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Piper Sandler, TD Cowen, and Wells Fargo & Company.
View the latest analyst ratings for CERE.

What is the current price target for Cerevel Therapeutics?

10 Wall Street analysts have set twelve-month price targets for Cerevel Therapeutics in the last year. Their average twelve-month price target is $41.40, suggesting a possible downside of 1.1%. JPMorgan Chase & Co. has the highest price target set, predicting CERE will reach $45.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $30.00 for Cerevel Therapeutics in the next year.
View the latest price targets for CERE.

What is the current consensus analyst rating for Cerevel Therapeutics?

Cerevel Therapeutics currently has 8 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CERE, but not buy more shares or sell existing shares.
View the latest ratings for CERE.

What other companies compete with Cerevel Therapeutics?

How do I contact Cerevel Therapeutics' investor relations team?

Cerevel Therapeutics' physical mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The biotechnology company's listed phone number is 844-304-2048 and its investor relations email address is [email protected]. The official website for Cerevel Therapeutics is ceres.net. Learn More about contacing Cerevel Therapeutics investor relations.